Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.580
-0.030 (-1.86%)
At close: Oct 7, 2025, 4:00 PM EDT
1.571
-0.009 (-0.59%)
After-hours: Oct 7, 2025, 7:19 PM EDT

Company Description

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.

It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.

The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.

Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.

Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.

Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals logo
CountryIsrael
Founded2000
IPO DateMar 13, 2014
IndustryBiotechnology
SectorHealthcare
Employees6
CEOAllen Baharaff

Contact Details

Address:
16 Abba Hillel Road
Ramat Gan, 5250608
Israel
Phone972 3 693 8448
Websitegalmedpharma.com

Stock Details

Ticker SymbolGLMD
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595353
CUSIP NumberM47238106
ISIN NumberIL0011313900
Employer ID98-1147233
SIC Code2834

Key Executives

NamePosition
Allen BaharaffCo-Founder, President, Chief Executive Officer and Chairman
Doron CohenChief Financial Officer
Guy NehemyaChief Operating Officer and Data Protection Officer
Yohai Stenzler CPAChief Accounting Officer
Dr. Liat Hayardeny MBA, Ph.D.Chief Scientific Officer
Dr. Tali GorfineMedical Consultant

Latest SEC Filings

DateTypeTitle
Sep 19, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 19, 20256-KReport of foreign issuer
Sep 2, 2025EFFECTNotice of Effectiveness
Sep 2, 2025EFFECTNotice of Effectiveness
Aug 28, 2025POS AMPost-Effective amendments for registration statement
Aug 28, 2025POS AMPost-Effective amendments for registration statement
Aug 28, 20256-KReport of foreign issuer
Aug 25, 20256-KReport of foreign issuer
Aug 21, 2025EFFECTNotice of Effectiveness
Aug 21, 2025424B3Prospectus